Digest Network Come funziona
Network
/
Società
Be
Non verificato

BeOne Medicines Ltd.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

32 comunicati stampa

Guarda tutti i comunicati
13/01/2026
Web e Social Network
Eventi
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
06/01/2026
Eventi
Fiere
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
23/12/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Web e Social Network
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
18/12/2025
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
07/12/2025
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
26/11/2025
Eventi
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
20/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Industria
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
17/11/2025
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Industria
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Fonte
BeOne Medicines Ltd.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0